Gordon B. Mills, MD, PhD, Oral History Interview, May 23, 2016

Gordon B. Mills, MD, PhD, Oral History Interview, May 23, 2016

Files

Download Interview Transcript (497 KB)

Download Navigation Materials (85 KB)

Loading...

Media is loading
 

Description

Major Topics Covered:

  • Personal background; educational path
  • Professional path prior to MD Anderson
  • Research areas: immunology, targeted therapy, interleukin-2, Women’s Cancer Moon Shot
  • Institutional development: Department of Systems Biology, Kleberg Institute, Zayed Institute

Identifier

MillsG_01_20160523

Publication Date

5-23-2016

Publisher

The Making Cancer History® Voices Oral History Collection, The University of Texas MD Anderson Cancer Center

City

Houston, Texas

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.

Topics Covered

University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center, University of Texas System. M.D. Anderson Cancer Center, M.D. Anderson Hospital and Tumor Institute at Houston, University of Texas M.D. Anderson Cancer Center, M.D. Anderson Hospital and Tumor Institute

Disciplines

History of Science, Technology, and Medicine | Oncology | Oral History

About the Interview

Gordon B. Mills, MD, PhD (b. 3 August 1953, Edmonton, Canada) was recruited to MD Anderson in 1994 to Chair the Department of Molecular Oncology and serve as Chief of the Section of Molecular Therapeutics. In 2006 he founded the first systems biology department focused on cancer in the US. He has served as Chair of the Department of Systems Biology [in the Division of Science] since that time. He has served as co-director of the Zayed Institute for Personalized Cancer Therapy, since 2010 and co-head of the Women's Cancer Moon Shot since 2013. Dr. Mills’ research focuses on the PI3K pathway, lysophospholipids, the genomics and genetics of women’s cancers, and identifying and characterizing a number of potential oncogenes and tumor suppressor genes.

Conditions Governing Access

Open

Gordon B. Mills, MD, PhD, Oral History Interview, May 23, 2016

Share

COinS